FDA Warns of Health Risks with Off-label Antipsychotics

JUNE 01, 2005
Ken Rankin

Newly discovered health risks for seniors taking certain "atypical antipsychotic drugs" for off-label indications have prompted the FDA to alert pharmacists and other health care providers to the problem.

The drugs-which include aripiprazole, olanzapine, clozapine, risperidone, and ziprasidone-are approved for the treatment of schizophrenia and mania. FDA officials, however, said that new research suggests that, when these products are prescribed off-label to treat behavioral disorders in elderly patients with dementia, a higher risk of death may result. Agency officials have raised the same concerns about a combination olanzapine and fluoxetine HCl formulation (Symbyax), a drug approved for the treatment of bipolar disorder.

In addition to alerting pharmacists to these problems, FDA officials have asked the manufacturers to place new boxed warnings on their drug labeling. The officials also are urging patients who have been taking the drugs for dementia or other off-label behavioral symptoms to have their therapy reviewed.

Mr. Rankin is a freelance medical writer.



SHARE THIS SHARE THIS
0

Immunization Laws Around the Nation

Many areas of medicine that intersect with law and immunizations are associated with a very specific set of laws across the nation.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.